Bluebird Bio Inc (BLUE)

[stocksrising]

I’m getting so many Alerts concerning tomorrow’s Oral presentation of Updated Long Term Data(ASH Conference ) that could be band aid for now!
ZYNTEGLO….

Also, you prob already saw BLUE’s Safe Harbor lingo ‘Expected, on or Before’ and MS saying somewhat similar:

Bluebird Bio, Inc.

BLUE
-39.5%
+ Free Alerts
shares are trading higher Friday after Morgan Stanley upgraded Bluebird Bio from Underweight to Equal-Weight and raised the price target to $7.

The Details:

Morgan Stanley analyst Jeffrey Hung upgraded Bluebird Bio from Underweight to Equal-Weight and raised the price target from $3 to $7 ahead of an expected FDA decision.

Hung said that Morgan Stanley believes the company's drug lovo-cel is likely to be approved for sickle cell disease
“by the December 20 PDUFA date”
and that the stock will continue to move up heading into the FDA decision.

Hung also said that they expect investor focus to return to the company's gradual launches for Skysona, Zynteglo, and lovo-cel in the longer term.

Bluebird Bio shares have grabbed the interest of short-sellers with 23.16% of available BLUE shares being sold short, according to the latest data from Benzinga Pro.

More importantly, the disapproval of PRV is mind boggling and perhaps more damaging:


The Company’s BLA for lovo-cel was previously accepted for priority review by the FDA for patients with sickle cell disease ages 12 and older who have a history of vaso-occlusive events (VOEs) and has a “Prescription Drug User Fee Act (PDUFA) GOAL date of December 20, 2023”. bluebird “may be eligible” for a PRV should lovo-cel be approved for patients under the age of 18”